Menu Search
Equities

Wellnex Life Ltd

22W0:DEU

Wellnex Life Ltd

Actions
  • Price (EUR)0.012
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 24 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Wellnex Life Ltd is an Australia-based company, which is engaged in the consumer healthcare business. The Company is developing, licensing, and marketing registered products and brands to customers in the healthcare market segment. Its brands include Wakey Wakey, Nighty Night, Pharmacy Own, The Iron Company, Mr Bright and Pain Away. The Company has intellectual property (IP)-licensing agreements with Haleon and Arrotex. The Company, through a joint venture with OneLife Botanical and Chemist Warehouse for SAS-B medicinal cannabis under the Wellness Life brand. It also offers Wagner Health Liquigesic through its joint venture with Chemist Warehouse. It owns the Therapeutic Goods Administration of Australia (TGA) registration of assorted liquid soft gel analgesics, which is licensed and/or supplied to pharmaceutical brands in Australia and offshore. Its products are distributed through Australia’s pharmacy wholesale retails and grocery retailers and supermarkets.

  • Revenue in AUD (TTM)20.31m
  • Net income in AUD-19.39m
  • Incorporated2011
  • Employees--
  • Location
    Wellnex Life Ltd17 / 71 Victoria Crescent, AbbotsfordMELBOURNE 3207AustraliaAUS
  • Phone+61 38399-9419
  • Websitehttps://wellnexlife.com.au/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.